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Since establishment of the Global Polio Eradication 
Initiative* in 1988, polio cases have declined >99.9% world-
wide; extensive use of live, attenuated oral poliovirus vaccine 
(OPV) in routine childhood immunization programs and mass 
campaigns has led to eradication of two of the three wild polio-
virus (WPV) serotypes (types 2 and 3) (1). Despite its safety 
record, OPV can lead to rare emergence of vaccine-derived 
polioviruses (VDPVs) when there is prolonged circulation or 
replication of the vaccine virus. In areas with inadequate OPV 
coverage, circulating VDPVs (cVDPVs) that have reverted 
to neurovirulence can cause outbreaks of paralytic polio (2). 
Immunodeficiency-associated VDPVs (iVDPVs) are isolated 
from persons with primary immunodeficiency (PID). Infection 
with iVDPV can progress to paralysis or death of patients with 
PID, and excretion risks seeding cVDPV outbreaks; both 
risks might be reduced through antiviral treatment, which is 
currently under development. This report updates previous 
reports and includes details of iVDPV cases detected during 
July 2018–December 2019 (3). During this time, 16 new 
iVDPV cases were reported from five countries (Argentina, 
Egypt, Iran, Philippines, and Tunisia). Alongside acute flac-
cid paralysis (AFP) surveillance (4), surveillance for poliovirus 
infections among patients with PID has identified an increased 
number of persons excreting iVDPVs (5). Expansion of PID 
surveillance will facilitate early detection and follow-up of 
iVDPV excretion among patients with PID to mitigate the 
risk for iVDPV spread. This will be critical to help identify all 
poliovirus excretors and thus achieve and maintain eradication 
of all polioviruses.
Classification of VDPVs and Identification 
of iVDPV
Poliovirus isolates are grouped into three categories: WPV, 
Sabin-related poliovirus, and VDPV (3). Sabin-related viruses 
have limited divergence in the capsid protein (VP1) nucleo-
tide sequences from the corresponding OPV (Sabin) strain: 
poliovirus types 1 and 3 (PV1 and PV3) are ≤1% divergent; 
poliovirus type 2 (PV2) is ≤0.6% divergent. VDPVs have 
clinical characteristics similar to those of WPV. VDPVs are 
>1% divergent (from PV1 and PV3) or >0.6% divergent (from 
PV2) in VP1 nucleotide sequences from the corresponding 
* http://polioeradication.org.
OPV strain (4). VDPVs are further classified as 1) circulating 
vaccine-derived polioviruses (cVDPVs), when there is evidence 
of community transmission; 2) iVDPVs, when they are isolated 
from persons with PIDs; and 3) ambiguous VDPVs (aVDPVs), 
when isolated from persons with no known immunodeficiency 
and when there is no evidence of community transmission or 
when isolates from sewage are not genetically linked to other 
known VDPVs and whose source is unknown (3).
A healthy person typically clears poliovirus infection within 
6 weeks. However, in persons with PIDs, an inability to mount 
an adequate humoral immune response can result in persistence 
of intestinal infection with poliovirus and prolonged viral 
shedding (5,6). The iVDPV case definition is a laboratory-
confirmed VDPV infection in a person of any age who has a 
primary humoral (B-cell) or combined humoral and cellular 
(B- and T-cell) immunodeficiency disorder (6). An iVDPV 
infection is persistent if VDPV is excreted for >6 months and 
chronic if excreted for >5 years (6).
Summary of iVDPV Epidemiology, 1961–2019
The World Health Organization (WHO) has compiled 
reports of iVDPV excretion since 1961 (6). As of May 2020, 
a total of 149 iVDPV cases had been reported to WHO from 
January 1961 through December 2019 (Table 1). These 
cases were detected through AFP surveillance (when paralysis 
occurred before PID was diagnosed) and by reports of iVDPV 
isolation from fecal specimens (when stool cultures were 
obtained from patients with suspected or diagnosed PID to 
detect enterovirus infection). The number of reported cases 
has increased over time: 66% of cases were detected during 
2010–2019. Most onsets occurred in children aged <2 years 
(59%); 60% of cases were in males; and 64% of patients had 
acute flaccid paralysis (AFP) as the first sign. The most com-
mon PID diagnoses were various antibody disorders, severe 
combined immunodeficiency disorder (SCID), and common 
variable immunodeficiency disorder.
During the reporting period, iVDPV type 2 (iVDPV2) has 
been the most prevalent serotype (56%), followed by iVDPV 
type 3 (iVDPV3) (23%) and iVDPV type 1 (iVDPV1) (17%), 
with 4% heterotypic mixtures (types 1 and 2 in 2% of cases 
and types 2 and 3 in 2%). Because WPV type 2 had been 
eradicated, in April 2016, all 155 OPV-using countries and 
territories switched from trivalent OPV (tOPV, containing 
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TABLE 1. Summary of 149 immunodeficiency-associated vaccine-
derived poliovirus (iVDPV) cases reported in the World Health 
Organization (WHO) iVDPV registry — worldwide, January 1, 1961–
December 31, 2019*
Characteristic No. (%)







Eastern Mediterranean 74 (49.7)
European 16 (10.7)
Americas 18 (12.1)
South-East Asian 15 (10.1)













Antibody disorders (HGG, AGG, XLA) 39 (28.1)
Common variable immunodeficiency 22 (15.8)
SCID and other combined humoral/T-cell deficiencies 46 (33.1)








1 and 2 3 (2.0)
2 and 3 3 (2.0)
Outcome
Alive 16 (10.7)
Alive and stopped excreting 52 (34.9)
Dead 65 (43.6)
Unknown/Lost to follow-up 16 (10.7)
Abbreviations: AGG = agammaglobulinemia; HGG = hypogammaglobulinemia; 
ICF = centromeric region instability, facial anomalies syndrome; MHC = major 
histocompatibility complex; SCID  =  severe combined immunodeficiency; 
XLA = X-linked agammaglobulinemia.
* Data as of May 17, 2020.
types 1, 2, and 3 Sabin strains) to bivalent OPV (bOPV, 
containing types 1 and 3 Sabin strains), to reduce the risk for 
paralytic disease from type 2 OPV (from vaccine-associated 
paralytic polio, which rarely occurs in OPV recipients and 
their susceptible close contacts; and from VDPV) (7). Since 
the tOPV-to-bOPV switch, the incidence of iVDPV2 cases 
has declined substantially, with iVDPV1 and iVDPV3 now 
the most prevalent serotypes (Figure). During 2000–2016, 
an average of 7.7 cases of iVDPV2 were identified per year 
(total = 54), compared with 0.67 cases per year (two cases) 
during 2017–2019. At the most recent follow-up, 16 patients 
(11%) were alive and still excreting iVDPV, 52 (35%) were 
alive and had stopped excreting, 65 (44%) had died, and 16 
(11%) were lost to follow up (Table 1).
Reported iVDPV Cases, July 1, 2018– 
December 31, 2019
During July 2018–December 2019, 16 new iVDPV cases 
were reported from five countries (Argentina, Egypt, Iran, 
Philippines, and Tunisia) (Table 2). These cases included eight 
iVDPV1 cases, seven iVDPV3 cases, and one iVDPV2 case, 
with no heterotypic mixtures. The cases are described below.
Argentina (one case). In 2018 AFP occurred in a girl aged 
9 months who had previously received 2 inactivated poliovi-
rus vaccine doses and 1 bOPV dose in November 2017. In 
November 2018, iVDPV3 (1.4% VP1 divergence) was detected 
in a stool specimen. The most recent detection (2.9% VP1 
divergence) was collected in August 2019; specimens collected 
since have been negative, the latest in November 2019. This 
patient had a diagnosis of agammaglobulinemia.
Egypt (10 cases). During July–December 2018, the PID 
surveillance project in Egypt identified six iVDPV infections, 
one in a patient who had developed AFP; two cases were 
iVDPV3 and four iVDPV1. Follow-up revealed that three 
patients had died, two patients stopped shedding, and one 
patient shedding iVDPV1 with 2.6% VP1 divergence con-
tinued to shed the virus for 22 months after the last reported 
bOPV dose. During 2019, four patients with iVDPV infection 
without AFP were detected; three patients had positive test 
results for iVDPV3, and one patient had a positive test result 
for iVDPV1. Two patients with iVDPV3 infection stopped 
excreting after 4 and 6 months.
Iran (three cases). In 2018, three iVDPV1 cases were 
reported, including a case detected before July 2018 and previ-
ously reported. These included cases in a boy aged 8 months 
with SCID who subsequently died and another in a boy aged 
11 months who developed AFP in November 2018 and is 
continuing to excrete, most recently in April 2020. In July 
2019, an iVDPV1 case was reported in a girl aged 7 months 
who had developed AFP; all seven specimens obtained from 
this patient contained iVDPV1.
Philippines (one case). An iVDPV2 case was detected in 
August 2019 in a boy aged 5 years who had received 3 doses 
of tOPV from 2014 to 2015. At his initial evaluation, he had 
severe malnutrition, significantly reduced antibody levels, and 
multiple signs and symptoms pointing to a complex immune 
disorder; however, no specific PID diagnosis was reported. 
Follow-up stool specimens collected from September 2019 
to May 2020 were positive for VDPV2. Concurrent with the 
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TABLE 2. Immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) detected — worldwide, July 2018–January 2020*
Country
Year 














Argentina 2018 AFP case AGG Nov 20, 2018 3 1.3 84 21 Stopped excreting
Egypt 2018 Non-AFP case CID Jul 15, 2018 3 1.6 95 10 Stopped excreting
Egypt 2018 Non-AFP case MHC II deficiency Aug 23, 2018 1 1.7 95 17 Died
Egypt 2018 Non-AFP case CID Sep 13, 2018 1 3.6 95 12 Stopped excreting
Egypt 2018 AFP case SCID Oct 18, 2018 1 2.6 95 4 Died
Egypt 2018 Non-AFP case MHC II deficiency Dec 16, 2018 3 1.6 95 4 Died
Egypt 2018 Non-AFP case SCID Dec 25, 2018 1 1.4 95 22 Alive and excreting
Iran 2018 Non-AFP case SCID Aug 14, 2018 1 1.0 99 6 Died
Iran 2018 AFP case B-cell deficiency Nov 23, 2018 1 1.6 99 22 Alive and excreting
Egypt 2019 Non-AFP case Unknown Feb 03, 2019 3 1.4 95 4 Stopped excreting
Egypt 2019 Non-AFP case SCID Mar 13, 2019 1 3.0 95 13 Alive and excreting
Egypt 2019 Non-AFP case SCID Jun 18, 2019 3 2.0 95 12 Alive and excreting
Egypt 2019 AFP case SCID Aug 28, 2019 3 1.9 95 6 Stopped excreting
Iran 2019 AFP case AGG Jul 11, 2019 1 1.3 99 10 Alive and excreting
Philippines 2019 AFP case Hypokalemia and 
infectious diarrhea
Aug 29, 2019 2 7.6 66 60 Alive and excreting
Tunisia 2019 AFP case MHC II deficiency Mar 12, 2019 3 4.1 97 18 Stopped excreting
Abbreviations: AFP = acute flaccid paralysis; AGG = agammaglobulinemia; CID = combined immunodeficiency disorder; MHC = major histocompatibility complex; 
OPV = oral poliovirus vaccine; PID = primary immunodeficiency disorder; SCID = severe combined immunodeficiency disorder.
 * Data as of May 17, 2020.
 † Percentage of divergence is estimated from the number of nucleotide differences in the capsid protein VP1 region from the corresponding parental OPV strain 
in the latest iVDPV sequence available.
 § Coverage with 3 doses of OPV, based on 2018 data from the World Health Organization (WHO) Vaccine Preventable Diseases Monitoring System (2018 global 
summary) and WHO-United Nations Children’s Fund coverage estimates https://www.who.int/gho/immunization/poliomyelitis/en/. National data might not 
reflect weaknesses at subnational levels.
 ¶ Duration of iVDPV replication was estimated from clinical record by assuming that exposure was from last known receipt of OPV (or date of birth where vaccination 
data was not available).
 ** Outcome as of last reported information.
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Summary
What is already known about this topic?
Immunodeficiency-associated vaccine-derived polioviruses 
(iVDPVs) emerge among persons with primary immunodeficien-
cies (PIDs) and rarely can persist. Persistent iVDPV infection can 
result in paralysis and potentially seed community transmission.
What is added by this report?
After the 2016 global removal of oral poliovirus vaccine type 2 
from routine immunization, the reported incidence of iVDPV 
type 2 infections markedly declined. Increasing surveillance 
among patients with PID has identified more iVDPV infections 
without paralysis.
What are the implications for public health practice?
Surveillance for iVDPV infections among patients with PID 
needs to be strengthened, and development of poliovirus 
antivirals needs to be accelerated to treat iVDPV infections to 
achieve and maintain eradication of all polioviruses.
detection of the iVDPV2, a cVDPV2 outbreak was detected 
in the Philippines (2). Current genetic evidence indicates that 
the virus in the patient with iVDPV2 and cases in the cVDPV2 
outbreak have similar genetic distance from parental OPV2 
strain (7% VP1 divergence) and might share a common origin.
Tunisia (one case). A boy aged 9 months with human leu-
kocyte antigen (HLA)-class II deficiency developed AFP in 
March 2019. The infant had previously received inactivated 
poliovirus vaccine and had no history of OPV vaccination. 
VDPV3 with 1.3%–4.1% VP1 divergence was detected in 
stool specimens collected during March–December 2019. The 
child had stopped excreting by March 2020.
Discussion
Most countries with AFP surveillance detect iVDPV in 
paralyzed children who then receive a diagnosis of one of the 
PIDs. However, many iVDPV cases occur in patients with PID 
without paralysis, and at present, are only detected through 
special studies or pilot projects of iVDPV surveillance in 
children with a diagnosed PID. The increase in the number of 
reported infections during 2010–2019 is likely a consequence 
of increased efforts to identify infection among patients with 
PID and improved methods to detect polioviruses. One half of 
the detected cases were from the WHO Eastern Mediterranean 
Region, likely related to more recent focus on PID surveillance 
in that region as well as higher rates of consanguineous mar-
riages, which lead to higher prevalence rates of PID (8). WHO 
has supported several countries in implementing pilot projects 
for iVDPV surveillance in children with PID, including Egypt, 
Iran, Pakistan, Sri Lanka, and Tunisia, and more recently, 
China and India. Additional countries are being identified in 
other WHO regions and encouraged to implement systematic 
surveillance in children with PID and without paralysis. WHO 
and partners have developed guidelines for iVDPV surveillance 
in patients with PID that should become an integral part of 
global poliovirus surveillance (9).
Detection of cVDPV2 in the Philippines was associated with 
detection of VDPV2 infection in an immunodeficient patient. 
This is the first time that an iVDPV and cVDPV linkage has 
been described in a large outbreak, and further genetic analy-
sis is in progress. It is, however, unclear how or whether the 
immunodeficient patient contributed to the cVDPV outbreak. 
The first identified poliovirus of the cVDPV2 outbreak was 
detected through environmental surveillance with 7% VP1 
divergence from parental Sabin type 2 OPV and multiple 
amino acid changes. The cVDPV2 outbreak was confirmed 
by isolation of genetically linked virus from multiple addi-
tional sewage samples and AFP cases. A higher proportion 
of nucleotide substitutions leading to amino acid changes is 
usually found in genomic sequences of identified iVDPV2 
from patients with PID.
Continued progress in the development of antiviral medica-
tions effective against polioviruses is needed to eliminate virus 
shedding in persons identified with persistent and chronic 
iVDPV infections. Pocapavir (a capsid inhibitor) has been 
administered on compassionate use basis for several patients 
excreting iVDPV, with mixed results (10). Complete clearing 
of virus has been observed in some recipients; however, rapid 
development of poliovirus resistance to Pocapavir has been 
frequently observed (10). Therefore, development of a treat-
ment combining Pocapavir with a protease inhibitor currently 
called V-7404 that is expected to avoid antiviral resistance 
is continuing. Intravenous immunoglobulin is available to 
treat patients with PID and poliovirus (as well as nonpolio 
enterovirus) infection. While antiviral development continues, 
intravenous immunoglobulin might improve clinical care. 
Expansion of PID surveillance will facilitate early detection 
and follow-up of iVDPV excretion among patients with PID 
to mitigate the risk for iVDPV spread. This will be critical 
to help identify all poliovirus excretors and thus achieve and 
maintain eradication of all polioviruses.
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